Intervention Review

You have free access to this content

Aromatase inhibitors for subfertile women with polycystic ovary syndrome

  1. Sebastian Franik1,*,
  2. Jan AM Kremer2,
  3. Willianne LDM Nelen3,
  4. Cindy Farquhar4

Editorial Group: Cochrane Gynaecology and Fertility Group

Published Online: 24 FEB 2014

DOI: 10.1002/14651858.CD010287.pub2


How to Cite

Franik S, Kremer JAM, Nelen WLDM, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010287. DOI: 10.1002/14651858.CD010287.pub2.

Author Information

  1. 1

    Radboud University Nijmegen, Faculty of Medical School, Nijmegen, Netherlands

  2. 2

    Radboud University Nijmegen Medical Center, Department of Obstetrics and Gynaecology, Nijmegen, Netherlands

  3. 3

    Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

  4. 4

    University of Auckland, Department of Obstetrics and Gynaecology, Auckland, New Zealand

*Sebastian Franik, Faculty of Medical School, Radboud University Nijmegen, Geert Grooteplein 9, PO Box 9101, Nijmegen, 6500HB, Netherlands. S.Franik@gmx.de.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 FEB 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 4]
Figure 4. Forest plot of comparison: 2 Aromatase inhibitors compared to other ovulation induction agents, outcome: 2.1 Live birth rate.
[Figure 5]
Figure 5. Forest plot of comparison: 2 Aromatase inhibitors compared to other ovulation induction agents, outcome: 2.6 Ovarian hyperstimulation syndrome rate.
[Figure 6]
Figure 6. Forest plot of comparison: 2 Aromatase inhibitors compared to other ovulation induction agents, outcome: 2.8 Clinical pregnancy rate.
[Figure 7]
Figure 7. Funnel plot of comparison: 2 Aromatase inhibitors compared to other ovulation induction agents, outcome: 2.8 Clinical pregnancy rate.
[Figure 8]
Figure 8. Forest plot of comparison: 3 Aromatase inhibitors compared to laparoscopic ovarian drilling, outcome: 3.1 Live birth rate.
[Figure 9]
Figure 9. Funnel plot of comparison: 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, outcome: 2.10 Impact of allocation bias for clinical pregnancy rate.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Aromatase inhibitors compared to placebo, Outcome 1 Live birth rate.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Aromatase inhibitors compared to placebo, Outcome 2 Ovarian hyperstimulation syndrome rate.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Aromatase inhibitors compared to placebo, Outcome 3 Clinical pregnancy rate.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Aromatase inhibitors compared to placebo, Outcome 4 Miscarriage rate per woman randomised.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Aromatase inhibitors compared to placebo, Outcome 6 Multiple pregnancy rate.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 1 Live birth rate.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 2 Live birth rate per BMI.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 3 Live birth rate per first or second line treatment.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 4 Impact of allocation bias for live birth rate.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 5 Impact of detection bias for live birth rate.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 6 Impact of attrition bias for live birth rate.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 7 Ovarian hyperstimulation syndrome rate.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 8 Ovarian hyperstimulation syndrome rate per BMI.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 9 Clinical pregnancy rate.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 10 Impact of allocation bias for clinical pregnancy rate.
[Analysis 2.11]
Analysis 2.11. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 11 Miscarriage rate per woman randomised.
[Analysis 2.12]
Analysis 2.12. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 12 Miscarriage rate per pregnancy.
[Analysis 2.13]
Analysis 2.13. Comparison 2 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts, followed by timed intercourse, Outcome 13 Multiple pregnancy rate.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI, Outcome 1 Ovarian hyperstimulation syndrome rate.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI, Outcome 2 Clinical pregnancy rate.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI, Outcome 3 Miscarriage rate per woman randomised.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI, Outcome 4 Miscarriage rate per pregnancies.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Aromatase inhibitors compared to clomiphene citrate with or without adjuncts followed by IUI, Outcome 5 Multiple pregnancy rate.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 1 Live birth rate.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 2 Ovarian hyperstimulation syndrome rate.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 3 Clinical pregnancy rate.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 4 Miscarriage rate per woman randomised.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 5 Miscarriage rate per pregnancies.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Aromatase inhibitors compared to laparoscopic ovarian drilling, Outcome 6 Multiple pregnancy rate.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Letrozole compared to anastrozole, Outcome 1 Ovarian hyperstimulation syndrome rate.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Letrozole compared to anastrozole, Outcome 2 Clinical pregnancy rate.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Letrozole compared to anastrozole, Outcome 3 Miscarriage rate per woman randomised.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Letrozole compared to anastrozole, Outcome 4 Miscarriage rate per pregnancies.
[Analysis 5.5]
Analysis 5.5. Comparison 5 Letrozole compared to anastrozole, Outcome 5 Multiple pregnancy rate.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Five days compared to 10 days administration protocol of letrozole, Outcome 1 Ovarian hyperstimulation syndrome rate.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Five days compared to 10 days administration protocol of letrozole, Outcome 2 Clinical pregnancy rate.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Five days compared to 10 days administration protocol of letrozole, Outcome 3 Miscarriage rate per woman randomised.
[Analysis 6.4]
Analysis 6.4. Comparison 6 Five days compared to 10 days administration protocol of letrozole, Outcome 4 Miscarriage rate per pregnancies.
[Analysis 6.5]
Analysis 6.5. Comparison 6 Five days compared to 10 days administration protocol of letrozole, Outcome 5 Multiple pregnancy rate.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Dosage studies of letrozole, Outcome 1 Ovarian hyperstimulation syndrome rate.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Dosage studies of letrozole, Outcome 2 Clinical pregnancy rate.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Dosage studies of letrozole, Outcome 3 Miscarriage rate per woman randomised.
[Analysis 7.4]
Analysis 7.4. Comparison 7 Dosage studies of letrozole, Outcome 4 Miscarriage rate per pregnancies.
[Analysis 7.5]
Analysis 7.5. Comparison 7 Dosage studies of letrozole, Outcome 5 Multiple pregnancy rate.